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Antiangiogenic Synergism of Integrin-Targeted
Fumagillin Nanoparticles and Atorvastatin
in Atherosclerosis
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Gregory M. Lanza, MD, PHD, FACC*
St. Louis, Missouri; and Andover, Massachusetts
O B J E C T I V E S Studies were performed to develop a prolonged antiangiogenesis therapy regimen
based on theranostic 3-targeted nanoparticles.
B A C KG ROUND Antiangiogenesis therapy may normalize atherosclerotic plaque vasculature and
promote plaque stabilization. 3-targeted paramagnetic nanoparticles can quantify atherosclerotic
angiogenesis and incorporate fumagillin to elicit acute antiangiogenic effects.
METHOD S In the ﬁrst experiment, hyperlipidemic rabbits received 3-targeted fumagillin
nanoparticles (0, 30, or 90 g/kg) with either a continued high fat diet or conversion to standard chow.
The antiangiogenic response was followed for 4 weeks by cardiac magnetic resonance (CMR) molecular
imaging with 3-targeted paramagnetic nanoparticles. In a second 8-week study, atherosclerotic
rabbits received atorvastatin (0 or 44 mg/kg diet) alone or with 3-targeted fumagillin nanoparticles
(only week 0 vs. weeks 0 and 4), and angiogenesis was monitored with CMR molecular imaging.
Histology was performed to determine the location of bound nanoparticles and to correlate the level of
CMR enhancement with the density of angiogenic vessels.
R E S U L T S The 3-targeted fumagillin nanoparticles reduced the neovascular signal by 50% to 75% at 1
week andmaintained this effect for 3 weeks regardless of diet and drug dose. In the second study, atherosclerotic
rabbits receiving statin alone had no antineovascular beneﬁt over 8 weeks. The 3-targeted fumagillin
nanoparticles decreased aortic angiogenesis for 3weeks as in study 1, and readministration onweek 4 reproduced
the 3-week antineovascular response with no carry-over beneﬁt. However, atorvastatin and 2 doses of 3-
targeted fumagillin nanoparticles (0 and 4weeks) achievedmarked and sustainable antiangiogenesis. Microscopic
studies corroborated the high correlation between CMR signal and neovessel counts and conﬁrmed that the
3-targeted nanoparticles were constrained to the vasculature of the aortic adventia.
CONC L U S I O N S The CMR molecular imaging with 3-targeted paramagnetic nanoparticles dem-
onstrated that the acute antiangiogenic effects of 3-targeted fumagillin nanoparticles could be prolonged
when combined with atorvastatin, representing a potential strategy to evaluate antiangiogenic treatment
and plaque stability. (J Am Coll Cardiol Img 2008;1:624–34) © 2008 by the American College of Cardiology
Foundation
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625therosclerotic plaque progresses from an early
atheromatous lesion to a thin-capped vulnera-
ble plaque through aggressive inflammatory
and immune responses, comprising macro-
hage infiltration with necrotic core enlargement,
eovascular expansion of the vasa vasorum, and in-
raplaque hemorrhage (1–3). Increased plaque angio-
enesis, driven by hypoxia (4), proangiogenic growth
actors (5), and oxidative stress (6), portends unstable
ascular disease (1,2). Angiogenesis is correlated with
laque rupture (1) and is associated with the morpho-
ogical features of vulnerable atheromas, including
acrophage-infiltrated fibrous caps (1), lipid-rich
ores (7), and thin-cap shoulders (1). The preponder-
nce of data from experimental models and human
athological samples indicates that plaque neovascu-
ature could serve as a molecular imaging biomarker of
therosclerotic severity and cardiovascular disease risk.
See page 635
Traditional therapies, such as 3-hydroxy-3-methyl-
lutaryl–coenzyme A reductase inhibitors, i.e., statins,
ave been proven to reduce cardiovascular risk (8), but
heir benefits may exceed the primary lipid-lowering
ffects. The pleiotropic benefits of statins have been
ttributed to antioxidant effects (9), diminished
eukocyte–endothelial cell adhesion (10), attenuated
acrophage activation and cytokine release (11), in-
reased endothelial nitric oxide activity (12), or ath-
rosclerotic plaque stabilization (13). Pathological data
rom excised carotid arteries of patients treated for
months with statins have revealed a reduction in
icrovascular density, which was proposed as an
xplanation for the additional benefit of statins (14).
thers have asserted that direct evidence of decreased
ntraplaque angiogenesis attributable to statins and
linical improvement is lacking, and a normalized
asculature achieved through neovascular pruning may
e less prone to intraplaque hemorrhage and may
romote plaque stabilization (3,15).
Three antivascular endothelial growth factor
rugs have been approved for use in specific cancers,
ut these drugs are expensive and have significant
dverse effects, including proteinuria, hypertension,
hrombosis, and intestinal perforation (16). Although
his risk-benefit profile is acceptable in the context
f cancer patient survival, the efficacy of these or
imilar drugs for the chronic treatment of patients
ith atherosclerosis is less clear. A potent clinically
ranslatable antiangiogenic strategy that provides
irect monitoring and treatment is needed for the
hronic management of atherosclerotic patients. RWe have shown that 3-targeted paramagnetic
anoparticles can be used to quantify angiogenesis
n atherosclerosis (17), and with the incorporation
f fumagillin this theranostic (i.e., therapeutic and
iagnostic) agent can deliver an acute antiangio-
enic effect (18). The overarching hypothesis of
hese studies was to determine whether the acute
enefits of 3-targeted fumagillin nanoparticles
ould be incorporated into a clinically translatable
egimen for testing the potential benefits of long-
erm antiangiogenesis therapy. Accordingly, the
rst objective of these studies was to define the
ntiangiogenic pharmacodynamics of a single 3-
argeted fumagillin nanoparticle dosage. The sec-
nd objective was then to determine if the antian-
iogenic effects of 3-targeted fumagillin
anoparticles used acutely could be sustained with
ral atorvastatin.
E T H O D S
3-targeted nanoparticle synthesis. The
3-targeted nanoparticles were prepared
imilar to previous reports (17–19). All
anoparticle emulsions comprised 20%
v/v) perfluorooctylbromide (Exfluor,
ound Rock, Texas), 1.3% to 2% (w/v)
f a surfactant comixture, 1.7% (w/v)
lycerin, and water for the balance. The
urfactant comixture for the paramag-
etic nanoparticles included 69.9 mol%
ecithin (Avanti Polar Lipids, Alabaster,
labama), 0.1 mol% peptidomimetic
v3-integrin antagonist (U.S. patent
,322,770) conjugated to polyethylene glycol2,000-
hosphatidylethanolamine (Avanti Polar Lipids)
nd 30 mol% gadolinium diethylene-triamine-
entaacetic acid– bis-oleate (Gateway Chemical
echnologies, St. Louis, Missouri). The fumagillin
Sigma, St. Louis, Missouri) was included at the
roportionate expense of lecithin in the surfactant
t 2 different levels corresponding to 30 or 90 g of
rug per milliliter of emulsion. The 3-targeted
hodamine nanoparticles incorporated 0.1 mol%
hodamine phosphatidylethanolamine in the sur-
actant mix at the expense of lecithin for fluorescent
icroscopy studies.
The v3-integrin antagonist used is a quinalone
onpeptide developed by Bristol-Myers Squibb
edical Imaging (U.S. patent 6,511,648), initially
eported as the 111In–1,4,7,10-tetraazacyclo-
odecane-N,N=,N==,N===-tetraacetic acid conjugate
A B B
A N D
AlkP
ALT
AST
amino
CMR
reson
GGT
glutam
MetA
aminoP748 and cyan 5.5 homologue TA145 (20)R E V I A T I O N S
A C R O N YM S
alkaline phosphatase
alanine aminotransferase
aspartate
transferase
cardiac magnetic
ance
gamma
yltransferase
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626v3-ligand has a 15-fold preference for the Mn
2-
ctivated receptor (21 nmol/l) (20) and a one-half
aximal inhibitory concentration (IC50) for v5,
51, and glycoprotein IIb/IIIa of 10 mol/l
Bristol-Myers Squibb Medical Imaging, Billerica,
assachusetts; DS Edwards and TD Harris, un-
ublished data, November, 2002). Nanoparticles
ave an IC50 of 50 pmol/l for the Mn
2-activated
v3-integrin (Kereos, St. Louis, Missouri; JL Keene
nd RA Beardsley, unpublished data, May, 2007).
xperimental design. All animal care and experi-
ental protocols were in accordance with Wash-
ngton University guidelines. New Zealand White
abbits (n  37; 10 to 12 weeks old; Charles River
aboratories, Wilmington, Massachusetts) were fed
0.25% cholesterol diet (Purina Mills, St. Louis,
issouri) for 100 days. In 1 study, animals either
ontinued on the high-cholesterol diet or were
onverted to standard chow after the targeted fum-
gillin treatment; however, the serum cholesterol
evels remained highly elevated over the course of
he study in all of the animals (1,374  67 mg/dl)
ndependent of treatment. Therefore, in the second
tudy, the high-cholesterol diet was continued with
r without atorvastatin alone or in combination
ith nanoparticle treatment.
TUDY 1. The hypothesis tested in study 1 was
hether a single pulsed dose of 3-targeted
umagillin nanoparticles could persistently suppress
ngiogenesis in the aortic wall. Animals were ran-
omly assigned to 1 of 6 treatment groups:
. 3-targeted paramagnetic nanoparticles with-
out fumagillin and 0.0% cholesterol (n  6).
. 3-targeted paramagnetic nanoparticles with-
out fumagillin and 0.25% cholesterol (n  8).
. 3-targeted paramagnetic nanoparticles with
fumagillin (30 g/kg body weight) and 0.0%
cholesterol (n  7).
. 3-targeted paramagnetic nanoparticles with
fumagillin (30 g/kg body weight) and 0.25%
cholesterol (n  6).
. 3-targeted paramagnetic nanoparticles with
fumagillin (90 g/kg body weight) and 0.0%
cholesterol (n  5).
. 3-targeted paramagnetic nanoparticles with
fumagillin (90 g/kg body weight) and 0.25%
cholesterol (n  5).
Therapeutic or control nanoparticles were admin-
stered IV on week 0 and cardiac magnetic resonance
CMR) molecular imaging of angiogenesis was re-
eated on weeks 1, 2, 3, and 4 using 3-targeted
aramagnetic nanoparticles (no drug). pTUDY 2. The hypothesis tested in study 2 was
hether combinational therapy with 3-targeted
umagillin nanoparticles and atorvastatin could sus-
ain the antiangiogenic effect observed in study 1.
abbits were maintained on the 0.25% cholesterol
iet throughout the study, with a portion of the
nimals receiving feed supplemented with atorvas-
atin (44 mg/kg). The following treatment combi-
ations were studied:
. 3-targeted paramagnetic nanoparticles with-
out fumagillin and without atorvastatin (n  5).
. 3-targeted paramagnetic nanoparticles with-
out fumagillin and with atorvastatin (n  8).
. 3-targeted paramagnetic nanoparticles with
fumagillin (30 g/kg body weight, baseline and
week 4) and without atorvastatin (n  5).
. 3-targeted paramagnetic nanoparticles with
fumagillin (30 g/kg body weight, baseline)
and with atorvastatin (n  8).
. 3-targeted paramagnetic nanoparticles with
fumagillin (30 g/kg body weight, baseline and
week 4) and with atorvastatin (n  8).
Aortic neovasculature signal was followed for 8
eeks with serial CMR molecular imaging at base-
ine and on weeks 1, 2, 4, 6, and 8. Before the last
maging session, blood was drawn to assess electro-
ytes, liver function, and hematology to assess the
hronic effects of the high-lipid diet and experi-
ental treatments. All samples were analyzed by
he Washington University Department of Com-
arative Medicine.
ISTOLOGY. A separate cohort of atherosclerotic
nimals (n  7) was used for histological determi-
ation of 3-targeted nanoparticle binding. In 1
nimal, 3-targeted rhodamine nanoparticles
ere injected and allowed to circulate for 3 h.
ifteen minutes before the animal was killed, fluo-
escein isothiocyanate (FITC)-labeled lectin was
dministered intra-arterially. Unbound nanopar-
icles and lectin were flushed from the vasculature
y saline perfusion. The aorta was excised, frozen in
ptimal cutting temperature compound medium,
ectioned, counterstained with 4’,6-diamidino-2-
henylindole, and examined with fluorescence mi-
roscopy. Adjacent sections were stained with he-
atoxylin and eosin for light microscopy.
In the remaining animals, CMR molecular im-
ging of angiogenesis was performed with 3-
argeted paramagnetic nanoparticles, followed by
illing the animals for histological measurement of
icrovessel density. Formalin-fixed samples werearaffin embedded, sectioned, and stained for the
e
I
e
I
d
i
M
t
i
i
h
s

m
f
u
S
b
c
t
t
p
s
C
f
s
d
d
r
d
a
o
a
i
a
t
t
t
t
3
p
i
i
s
m
S
g
v
g
l
t
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 1 , N O . 5 , 2 0 0 8
S E P T E M B E R 2 0 0 8 : 6 2 4 – 3 4
Winter et al.
Antiangiogenic Approaches to Atherosclerosis
627xpression of 3-integrin (LM-609, Chemicon
nternational, Temecula, California) and platelet/
ndothelial cell adhesion molecule 1 (Chemicon
nternational) (18). LM609-positive microvessel
ensity was measured in digitized images from 3
ndependent full-transverse sections per animal.
R molecular imaging of angiogenesis. The 3-
argeted paramagnetic nanoparticles (1 ml/kg) were
njected into the marginal ear vein. Animals were
maged before and 3 h after injection with a
igh-resolution, 2-dimensional, T1-weighted, fat-
uppressed turbo spin-echo sequence (250  250
m resolution, 4-mm-thick slices, TR/TE 380/11
s, 90° flip angle, SPIR fat suppression, turbo
actor 4, 6 signal averages, 12.5 min scan time)
sing a clinical 1.5-T scanner (Philips Medical
ystems, Andover, Massachusetts) and a quadrature
irdcage coil. Three imaging stacks were acquired
overing the descending thoracic aorta (10 slices),
he transverse aorta (5 slices), and the ascending
horacic aorta (5 slices). Saturation bands were
ositioned superior and inferior to the imaging
tacks to suppress signals from in-flowing blood.
MR image analysis. The CMR signal enhancement
rom the aortic wall was quantified using a custom
Figure 1. Segmentation of the Aortic Wall and Color-Coded Sig
(Top) Black blood image of the thoracic aorta (arrow) and segment
image. The color-coded overlay of signal enhancement (%) shows p
enhancement has clearly decreased due to the antiangiogenic effec
enhancement gradually increases at weeks 2 and 3 after fumagillin
identical to the week 0 image.emiautomated segmentation program previously escribed (17,18). Briefly, the aortic lumen was
efined in each 2-dimensional image with a seeded
egion-growing algorithm. The aortic wall was
efined by dilation of the luminal mask followed by
n automated threshold to obtain a consistent and
bjective region of-interest encompassing the entire
ortic wall (Fig. 1), which was evaluated by visual
nspection. Image intensity was normalized across
nimals and time points to a fiduciary marker (test
ube with 25 mol/l gadolinium diethylene-
riamine-pentaacetic acid in saline) placed within
he field of view. The percentage enhancement in
he CMR signal was calculated slice by slice in the
-h post-injection images relative to the average
re-injection CMR signal, providing an unbiased
ntegrated measurement of contrast enhancement
n the aortic wall. The aortic contrast data repre-
ents the mean enhancement of all properly seg-
ented slices.
tatistical analysis. All data were analyzed using
eneral linear models (i.e., regression, analysis of
ariance [ANOVA] and analysis of covariance), and
roup means for model effects were separated using
east-significant differences (p  0.05) (SAS Insti-
ute, Cary, North Carolina) and reported as mean
Enhancement Before and After Targeted Fumagillin Treatment
n of the vessel wall (outlined in yellow) is shown for the week 0
y areas of high angiogenesis. On the week 1 image, the signal
targeted fumagillin treatment. (Bottom) The level of signal
tment, until week 4, when the level of enhancement is practicallynal
atio
atch
t of
treastandard error of the mean.
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628E S U L T S
uration of antiangiogenic effect after treatment with
v3-integrin targeted fumagillin nanoparticles. At
aseline, the average percentage signal enhance-
ent from 3-targeted paramagnetic nanopar-
icles did not differ between treatment groups and
anged between 20% and 25% (Fig. 1). Consistent
ith previous reports, 3-targeted paramagnetic
ontrast was diffusely distributed across and within
lices, and the enhancement calculated represented
he average of all aortic voxels rather than a thresh-
lded subset (17,18). Targeted characterization of
3-integrin expression revealed that early CMR
eovascular signal enhancement did not differ be-
ween fat-fed animals switched to standard chow
Controls
0 1 2 3 4
Fumagillin
Cholesterol-rich
Normal Chow
*
* *
Controls
Fumagillin 30 µg/kg
Fumagillin 90 µg/kg
0 1 2 3 4
Week of Study
*
* *
Aortic Signal Enhancement up to 4 Weeks After Treatment With
Fumagillin Nanoparticles
l imaging of angiogenesis in untreated (triangles) and fumagillin-
imals remaining on high-cholesterol diet (squares) or switched to
w (circles). Fumagillin treatment at week 0 reduced angiogenesis
with untreated control animals (*p  0.05), but withdrawing the
sterol feed had no effect. (Bottom) Aortic angiogenesis in rabbits
atment (triangles), with 30 g/kg fumagillin (circles), or with 90
agillin (squares). Fumagillin treatment at 30 versus 90 g/kg pro-
tical responses. *p  0.05.nd those continuing on the cholesterol-enriched Fiet over the 4-week study, which reflects the
arked serum cholesterol and fatty livers observed
n all of the animals. For clarity of presentation,
hese treatment groups were pooled (i.e., control).
In the top panel of Figure 2, the overall effects of
3-targeted fumagillin nanoparticles on aortic
eovascular contrast as a function of post-treatment
iet are presented. At week 1, neovascular contrast
mong animals receiving 3-targeted fumagillin
anoparticles was decreased by approximately 50%
o 75% relative to the control animals (p  0.05).
he decreased neovascular signal persisted through
eek 2. On week 3, aortic angiogenesis remained
ess than the control (p  0.05) in both dietary
roups, but the difference was smaller, indicating
hat the effect of fumagillin was waning. By week 4,
here was no difference in the CMR neovasculature
ignal between control and fumagillin-treated rab-
its, regardless of diet.
No change (p 0.05) in antiangiogenic response
rofile was found by increasing the fumagillin dose
rom 30 to 90 g/ml over the 4-week period (Fig.
). Although no difference in antiangiogenic re-
ponse was appreciated between drug loading levels,
he higher dose exhibited a trend toward longer
ffectiveness compared with its own signal enhance-
ent at baseline.
ntiangiogenic synergism of 3-targeted fumagillin
anoparticles and atorvastatin. Consistent with the
arlier 4-week experiment, the CMR signal en-
ancement from 3-targeted paramagnetic nano-
articles averaged between 20% and 25% at baseline
Fig. 3). The neovascular contrast enhancement
mong hyperlipidemic control rabbits was constant
ver the 8-week study. Therapy with atorvastatin
id not affect the CMR angiogenic signal at these
ime points. The top panel of Figure 3 shows that
3-targeted fumagillin nanoparticles elicited the
ame acute antiangiogenic response as observed
reviously in the present study and in our previous
eport (18). The first dosage of 3-targeted fum-
gillin nanoparticles decreased the angiogenic signal
or 2 weeks followed by a return to the baseline level
fter 4 weeks. The second administration of 3-
argeted fumagillin nanoparticles mirrored the an-
iangiogenic effects observed after the first dosage,
uggesting that the antineovascular response was
ot influenced by the preceding drug treatment.
The antiangiogenic effects of atorvastatin alone
nd in combination with 3-targeted fumagillin
anoparticles given once (baseline) or twice (base-
ine and week 4) are presented in the lower panel ofSi
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629MR signal enhancement from the aortic neovas-
ulature over the 8-week study. Administration of
ietary atorvastatin and a single dose of 3-
argeted fumagillin nanoparticles at baseline pro-
uced no change in the antiangiogenic response
attern. In addition, continued dietary atorvastatin
ollowing fumagillin treatment during the first
-week period did not elicit an antiangiogenic effect
uring weeks 4 to 8.
Serial treatment with 3-targeted fumagillin
anoparticles at baseline and week 4 in conjunction
ith dietary atorvastatin resulted in the expected
harmacodynamic 4-week cyclic pattern observed
reviously (Fig. 2). However, the antiangiogenic
esponse to the second dose of 3-targeted fum-
gillin nanoparticles was sustained by atorvastatin
ather than returning to baseline levels. The CMR
eovascular signals on weeks 6 and 8 after the
econd fumagillin treatment remained at less than
ne-half of the baseline contrast levels. Although
torvastatin alone exerted no significant effect on
laque angiogenesis in this short study, it is clear
hat dietary statin therapy can sustain the acute
ntineovascular benefits of 3-targeted fumagil-
in. The additive effects of fumagillin or statin alone
ere far less than the synergistic effect of both
ogether. In the ANOVA, this was reflected by the
nteraction term (statin  fumagillin) p value of
0.0001, signifying a nonparallel response.
linical pathology. Blood samples drawn at the end
f the 8-week study were assessed for hematology,
lectrolytes, and liver function (Fig. 4) and com-
ared with laboratory reference ranges published by
he University of Minnesota Research Animal Re-
ources program. Leukocyte, hemoglobin, hemato-
rit, and electrolyte (sodium, potassium, and chlo-
ide) values were within the normal range for
abbits and did not differ among treatment groups
p  0.05). Platelet count averages were similar
p  0.05) across treatments (370,000) and ele-
ated somewhat compared with the reported nor-
al upper limit for rabbits (270,000), which is
onsiderably lower than the normal limit for other
ammalian species.
Alkaline phosphatase (AlkP) was 2- to 3-fold
igher than the normal upper limit for all treatment
roups, which was numerically highest in the con-
rol animals but not statistically different (p 
.05). Gamma glutamyltransferase (GGT) was
imilar among treatment groups (p 0.05), but like
lkP it was numerically highest in the controlabbits. Because a published normal range for GGT en rabbits was unavailable, the normal range for
ther nonhuman mammals was used. Aspartate
minotransferase (AST) was well within the normal
imits and did not differ among treatment groups
p  0.05). Alanine aminotransferase (ALT) was
ncreased (p  0.05) in rabbits receiving 2 doses of
umagillin and dietary statin compared with the
ormal range and the other treatment groups.
nterestingly, the statin-only group also showed
lightly elevated ALT compared with the control
nd fumagillin-alone groups. Although dietary sta-
in combined with a single dose of 3-targeted
umagillin nanoparticles elevated ALT higher than
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Figure 3. Cardiac Magnetic Resonance Signal Enhancement up
Weeks After Treatment With Targeted Fumagillin Nanoparticles
and Without Oral Atorvastatin
(Top) Cardiac magnetic resonance enhancement in untreated (trian
atorvastatin-treated (circles) and fumagillin-treated animals (square
8 weeks of follow-up imaging. Untreated and statin-treated animals
a constant level of angiogenesis in the aortic wall. Animals treated
geted fumagillin nanoparticles at 0 and 4 weeks showed decreased
genesis (*p  0.05) after each dose, which returned to baseline lev
4 weeks. (Bottom) Enhancement in rabbits receiving atorvastatin al
angles) or in conjunction with 1 (squares) or 2 (circles) doses of ta
fumagillin nanoparticles. The combination of 2 fumagillin doses and
produced a sustained decrease in angiogenesis (*p  0.05).8
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630ormal range. Clinical pathology responses were
ncorrelated with serum cholesterol level.
The increased AlkP and GGT values and the
rank yellow discoloration of rabbit livers noted on
ecropsy suggested a marked fatty liver pathology
ithout concomitant hepatobiliary disease. The
ncrease in ALT in relation to AST also points to
ild subclinical hepatic insult by statins alone,
hich are known to induce liver enzyme release,
nd in combination with the perfluorocarbon nano-
articles, which are predominantly cleared by the
iver reticular endothelial cells (21).
istology. Fluorescence microscopy confirmed that
3-targeted rhodamine nanoparticles were dis-
ributed in the aortic adventia and were colocalized
ith FITC-lectin bound to vascular endothelium
Fig. 5). The 3-targeted rhodamine nanopar-
icles were not observed in the extravascular regions
f the adventia or within plaque.
The microvascular density followed a logarithmic
elationship (R2  0.84), with the CMR signal
nhancement of 3-targeted paramagnetic nano-
articles (Fig. 6). Neovascular signal enhancement
ncreased monotonically at higher advential mi-
rovessel counts and declined rapidly as neovessel
*
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Figure 4. Liver Function Enzymes After 8 Weeks of Atorvastatin
Blood samples drawn at the end of the 8-week study were assessed
lipid diet and experimental treatments. All values tended to be with
phosphate (AlkP), however, was elevated in all groups, and alanine
targeted fumagillin nanoparticles and oral statin (Fum 2  Statin)
GGT  gamma glutamyltransferase; NS  not signiﬁcant.ounts decreased. tI S C U S S I O N
n the present study, we demonstrated the concept
f a prolonged antiangiogenic regimen with poten-
ial for clinical translation using a nanomedicine-
ased strategy, which offers CMR molecular imag-
ng for patient stratification and monitoring and
argeted drug delivery. Using CMR molecular im-
ging with 3-targeted paramagnetic nanopar-
icles, the pharmacodynamic antiangiogenic effec-
iveness of a single low dose of 3-targeted
umagillin nanoparticles was found to persist for 3
eeks regardless of drug loading, after which con-
inued inflammation led to a recrudescence of the
eovasculature to baseline levels. Atorvastatin alone
id not induce neovascular changes detectable by
MR molecular imaging with 3-targeted para-
agnetic nanoparticles over 8 weeks of study;
owever, the combination of targeted fumagillin
anoparticles and atorvastatin synergistically sus-
ained the antiangiogenic effect. Microscopic stud-
es corroborated the high correlation between CMR
ignal and neovessel counts and reconfirmed that
he 3-targeted nanoparticles were constrained to
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631The integrin-targeted nanoparticles incorporated
ery low dosages of fumagillin, a mycotoxin pro-
uced by Aspergillus fumigatus that suppresses
ngiogenesis by inhibition of methionine amino-
eptidase 2 (22). Methionine aminopeptidase 2 is
esponsible for cleavage of the NH2-terminal me-
hionine residue from nascent proteins (23) and is
p-regulated during cellular proliferation (24).
NP-470 is a water-soluble form of fumagillin
hich shares the active ovalicin core and analo-
ously inhibits proliferating endothelial cells (i.e.,
ngiogenesis) with little effect on nonendothelial
ell types (25). TNP-470 has been studied in
uman clinical cancer trials, and anecdotal cases of
isease remission, regression, or stabilization have
een reported (26,27). Unfortunately, TNP-470
xhibited significant side effects at dosages required
or therapeutic effects (60 to 100 mg/kg, serially),
ncluding sudden moderately severe symptoms of
Figure 5. 3-Targeted Nanoparticles Bind to the Advential Va
Routine light microscopy and ﬂuorescence microscopy of 3-targ
labeled lectin, a vascular endothelial marker, enables localization of
lar structures. (A) Hematoxylin and eosin staining of aorta shows sm
image demonstrates colocalization of rhodamine-labeled 3-targe
ing that the nanoparticles are vascularly constrained to the neovess
ticles were detected in the lumen plaque (not shown).eurotoxicity. In the current nanoparticle applica- iion, the equivalent dosage of fumagillin (the parent
ompound) was 10,000-fold less than the total drug
ose used in a prior murine apolipoprotein E/
therosclerotic model (28) yet still achieved remark-
ble end point efficacy. Similarly, the total gadolin-
um dose used in these experiments is about 100
imes lower than that approved for clinical contrast
maging, which should diminish the potential for
ephrogenic systemic fibrosis, which has been re-
orted in patients with advanced renal disease or
iver transplantation (29).
Ligand-directed perfluorocarbon nanoparticles
re a theranostic platform technology targeted in
his case to proliferating endothelial cells. The
argeted v3-integrin is a heterodimeric trans-
embrane glycoprotein that is differentially up-
egulated in proliferating versus quiescent endothe-
ial cells but also expressed by numerous cell types
rominently represented in atherosclerotic plaques,
lature
rhodamine nanoparticles and ﬂuorescein isothiocyanate (FITC)-
oparticle binding with respect to normal and pathological vascu-
plaque, media and adventia (10). (B) High-power ﬂuorescent
nanoparticles (C, 60) with FITC-labeled lectin (D, 60), indicat-
of the adventitia. No rhodamine-labeled 3-targeted nanopar-scu
eted
nan
all
ted
elsncluding endothelial cells (30,31), macrophages
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63232), platelets (33), lymphocytes (33), and smooth
uscle cells (34). In this study, fluorescence micros-
opy demonstrated that perfluorocarbon nanoparticles
250 nm) were confined to endothelial targets within
he advential microvasculature at the time of imaging.
The potential role of antiangiogenic therapy in
he treatment of atherosclerosis has garnered in-
reasing scientific discussion both for (15,35) and
gainst (2,36) it. Although there is general agree-
ent that angiogenesis is a prominent feature of
ulnerable and ruptured plaques versus more stable
brocalcific lesions, questions regarding the caus-
tive relationship and clinical relevance of antian-
iogenic therapeutic strategies in cardiovascular dis-
ase have been raised. In the present work, we have
hown how a theranostic nanomedicine approach
an be interwoven with standard clinical practice to
rovide a sustained antiangiogenic regimen. More-
ver, noninvasive CMR longitudinal monitoring of
therosclerotic disease with 3-targeted paramag-
etic particles alone or enhanced with CMR intra-
laque hemorrhage assessment (37) offers an attrac-
ive quantitative approach to continued medical
anagement, particularly in asymptomatic patients.
tudy limitations. The utility of the New Zealand
hite atherosclerotic rabbit model derives from
he development of an early-expanded vasa vaso-
Vessels/Field
y = 6.65Ln(x) + 5.088
R2 = 0.8357
5 10 15 20
CMR Enhancement With 3-Targeted Nanoparticles
s to the Density of Angiogenic Microvessels
agnetic resonance (CMR) molecular imaging of angiogenesis with
eted paramagnetic nanoparticles and histological measurement of
el density was performed on a separate cohort of atherosclerotic
ortic sections were stained for 3-integrin (LM-609) and platelet/
al cell adhesion molecule (PECAM), a general vascular marker. The
f microvessels expressing both v3-integrin and PECAM were
n 3 independent full-transverse sections per animal. The number
enic microvessels per high-powered ﬁeld was correlated in a loga-
shion (R2  0.84) to the CMR signal enhancement observed after
of 3-targeted particles.um and neovasculature in response to the lipid- tnfiltrated aortic wall. Unfortunately, many fea-
ures of human vulnerable plaque are lacking,
ncluding intraplaque hemorrhage, fibrous cap
hinning, and plaque rupture. Therefore, impor-
ant questions surrounding the hypothesis that
ntiangiogenic treatment will prevent or reduce
he incidence of intraplaque hemorrhage as a
esult of neovessel pruning is poorly addressed in
his animal model. Moreover, this model does
ot develop CMR-visible lesions, which pre-
ludes the use of CMR with endogenous contrast
37,38) for monitoring plaque size and/or com-
osition, whereas other animal models involving
alloon injury, de-endothelialization, and genetic
odifications more closely mimic certain pathol-
gy features of vulnerable plaques, such as large
ipid cores. None of the models compatible with
anoparticle research fully embrace the morpho-
ogic complexity and biochemical interplay of the
uman atherosclerotic plaque.
Additionally, hyperlipidemic rabbits suffer in-
reased morbidity beyond 150 days on chronic
holesterol diet, which precluded determining the
ong-term duration of reduced angiogenesis
chieved in the group receiving fumagillin (2) and
tatin. Finally, one might reasonably speculate that
single dose of fumagillin following a month of
tatin treatment could yield a similar sustained
eduction of atherosclerotic angiogenesis, which
ould be more desirable from patient safety, com-
liance, and health care cost perspectives.
Although we did not repeat competitive binding
tudies in these experiments due to logistic con-
traints, we demonstrated previously that these
3-targeted nanoparticles bind specifically to the
eovascular endothelium with high affinity and
vidity (17). The reproducibility of the present and
revious CMR imaging results and the targeted
ntiangiogenic effects over multiple cohorts of rab-
its, together with the “washout” studies showing
ecrudescence without continued therapy followed
y efficacy upon retreatment, corroborate the ro-
ustness of this agent for diagnostic imaging and
argeted drug delivery in vivo.
O N C L U S I O N S
thers have postulated that antiangiogenesis therapy
ay normalize atherosclerotic plaque vasculature
hrough neovascular pruning, which could diminish
ntraplaque hemorrhage frequency and promote
laque stabilization. The overarching hypothesis ofCM
R 
En
ha
nc
em
en
t (%
)
20
10
30
0
0
Figure 6.
Correlate
Cardiac m
3-targ
microvess
rabbits. A
endotheli
number o
counted i
of angiog
rithmic fahe present studies was to determine whether the
a
l
t
o
n
p
d
t
g
l
t
i
a
s
A
T
H
E
A
w
p
R
L
F
B
R
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 1 , N O . 5 , 2 0 0 8
S E P T E M B E R 2 0 0 8 : 6 2 4 – 3 4
Winter et al.
Antiangiogenic Approaches to Atherosclerosis
633cute antiangiogenic effects of 3-targeted fumagil-
in nanoparticles could be incorporated into a clinically
ranslatable regimen for testing the potential benefits
f long-term antineovascular therapy. Cardiac mag-
etic resonance molecular imaging with 3-targeted
aramagnetic nanoparticles was used to noninvasively
emonstrate that a single minute dose of 3-
argeted fumagillin nanoparticles decreased aortic an-
iogenesis for 3 weeks and that this effect was pro-
onged with the addition of atorvastatin. This
heranostic nanomedicine approach could translate
nto a clinically relevant strategy to evaluate prolonged
ntiangiogenic treatment and atherosclerotic plaque567–72. rosis with alpha(cknowledgments
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